Novartis Income Tax Expense from 2010 to 2024

NVS Stock  USD 104.80  0.97  0.92%   
Novartis Income Tax Expense yearly trend continues to be comparatively stable with very little volatility. Income Tax Expense will likely drop to about 523.5 M in 2024. From the period from 2010 to 2024, Novartis Income Tax Expense quarterly data regression had r-value of (0.29) and coefficient of variation of  31.63. View All Fundamentals
 
Income Tax Expense  
First Reported
2000-03-31
Previous Quarter
595 M
Current Value
200 M
Quarterly Volatility
392.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many indicators such as Price To Sales Ratio of 3.86, Dividend Yield of 0.0241 or PTB Ratio of 3.23. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Novartis AG ADR over the last few years. It is Novartis' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
       Timeline  

Novartis Income Tax Expense Regression Statistics

Arithmetic Mean1,363,915,271
Geometric Mean1,282,011,002
Coefficient Of Variation31.63
Mean Deviation315,605,550
Median1,416,000,000
Standard Deviation431,459,184
Sample Variance186157T
Range1.6B
R-Value(0.29)
Mean Square Error183587.2T
R-Squared0.08
Significance0.29
Slope(28,002,870)
Total Sum of Squares2606198.4T

Novartis Income Tax Expense History

2024523.5 M
2023551 M
20221.4 B
20212.1 B
20201.8 B
20191.8 B
20181.2 B

About Novartis Financial Statements

Novartis shareholders use historical fundamental indicators, such as Income Tax Expense, to determine how well the company is positioned to perform in the future. Although Novartis investors may analyze each financial statement separately, they are all interrelated. The changes in Novartis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Novartis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Income Tax Expense551 M523.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.